Corrigendum to “Engineering aortic valves via transdifferentiating fibroblasts into valvular endothelial cells without using viruses or iPS cells” Bioact. Mater. 45 (2025), 181–200

Key Points

• Engineering aortic valves is possible through the transdifferentiation of fibroblasts
• The process does not rely on viruses or induced pluripotent stem cells, ensuring safety and efficiency.
• The observational analysis reveals the use of bioactive materials can enhance tissue engineering outcomes.
• This approach may enable novel treatments for heart valve diseases, but further validation is necessary.